Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial
Richard Odame Phillips, Jérome Robert, Kabiru Mohamed Abass, William A. Thompson et autres
BACKGROUND: Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment with oral rifampicin 10 mg/kg plus intramuscular streptomycin 15 …
Ghana, fr, Tunisie, Bénin, gb, us, Congo, nl, ch (code pays fourni par la source)
113 citations
The Lancet